BioPharma

The supplemental Biologics License Application - sBLA for Enhertu - trastuzumab deruxtecan by AstraZeneca and Daiichi Sankyo has been accepted as well as granted Priority Review in the U.S. when it comes to the treatment of adult patients with...

Sanofi has committed up to $1.53 billion to obtain global rights to a novel therapy from Sino Biopharmaceutical, adding a first-in-class JAK/ROCK inhibitor to its hematology and immunology pipeline. The French pharmaceutical group will make an upfront payment of...

On February 17, 2026, GSK plc announced that the European Commission approves Exdensur - depemokimab in two indications - As an add-on maintenance treatment when it comes to critical asthma with type 2 inflammation that stands characterised by a blood eosinophil...

Modern biopharmaceutical facilities are leveraging advanced automation to enhance the production of complex biologics, ensuring real-time quality control and operational efficiency.

Analysis of the evolving landscape of parenteral delivery, focusing on the stability of high-concentration biologics and the integration of patient-centric delivery devices.

Asia-Pacific’s biotechnology landscape is not just growing it is transforming. In 2026, the region stands at a unique crossroads where scientific ambition meets real-world demands. This year will test the industry’s resilience, shape global health priorities, and redefine how...

AstraZeneca has gone ahead and committed $100 million to head deeper into the KRAS space by way of securing the right when it comes to a clinical-stage, multitarget asset from Jacobio Pharma of China. The U.K.-based pharma giant has scored...